Article
Changes in survival of patients with non-small cell lung cancer in Japan: An interrupted time series study.
Cancer science - 1 Mar 2023
Taniyama Yukari, Oze Isao, Koyanagi Yuriko N, Kawakatsu Yukino, Ito Yuri, Matsuda Tomohiro, Matsuo Keitaro, Mitsudomi Tetsuya, Ito Hidemi
Abstract excerpt
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib were approved for metastatic or relapsed non-small cell lung cancer (NSCLC) in Japan in 2002 and 2007, respectively. EGFR mutation testing was also approved in 2007. Although clinical trials showed efficacy in NSCLC patients harboring activating EGFR mutations, these effects have rarely been reported in real-world...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.